Tag

Pancreatic Cancer

All articles tagged with #pancreatic cancer

business19 hours ago•19 min saved

Rasonque poised to reshape pancreatic cancer therapy with blockbuster potential

Revolution Medicines’ pancreatic cancer drug Rasonque will list at $39,800 for a 30-day supply, a price analysts say could help it become a blockbuster; Evercore ISI raised pancreatic cancer sales forecasts to about $2.4 billion next year and up to $15.1 billion by 2034, with potential expansion to other cancers. The FDA approved the drug for patients who’ve had one systemic therapy or aren’t candidates for multiagent therapy, and a Phase 3 front-line trial is underway, signaling strong launch momentum despite the steep price.

via BioPharma Dive|

#business #drug-pricing #fda-approval

health22 hours ago•19 min saved

Pancreatic cancer drug arrives with a $39,800 monthly price, but costs depend on coverage and aid

FDA approves Revolution Medicines’ oral daraxonrasib (Rasonque) for metastatic pancreatic adenocarcinoma after phase 3 results showing a 60% reduction in death risk and median survival of 13.2 months versus 6.7 with chemotherapy. The wholesale list price is about $39,800 for a 30‑day supply (roughly $477,000/year), but patients’ out‑of‑pocket costs vary with insurance; Medicare Part D and discounts can reduce costs by about 20–30%, and aid programs (e.g., Path) may offer low or zero copays for eligible patients. Side effects include rash, diarrhea, mucositis, nausea, fatigue, and edema. The drug is not a cure but offers a life‑extending option for a historically hard‑to‑treat cancer; about 67,000 pancreatic cancer diagnoses are expected in 2026.

via Yahoo Finance|

#drug-pricing #fda-approval #financial-assistance

healthcare1 day ago•5 min saved

Rasonque Debuts in Pancreatic Cancer as Investors Eye a Historic Launch

Revolution Medicines wins FDA approval for Rasonque (daraxonrasib) in metastatic pancreatic cancer, triggering optimism of a historic oncology launch and potential multi‑billion sales, but raising questions about first‑line use, payer coverage, and how quickly patients move from expanded‑access to commercial treatment amid a $39,800 monthly price and a broad label whose criteria for multiagent therapy remain unclear.

via Fierce Pharma|

#drug-pricing #expanded-access-program #healthcare

health1 day ago•39 min saved

KRAS-targeting pancreatic cancer pill approved, signaling a broader oncology breakthrough

The FDA approved Revolution Medicines’ Rasonque, a daily KRAS-targeting pill for adults with metastatic pancreatic adenocarcinoma after one prior therapy or when chemotherapy isn’t feasible. In trials, median overall survival more than doubled (13.2 months vs 6.7) and death risk was reduced by about 60%, with no KRAS mutation test required. Priced at $39,800 per 30 days and backed by patient-support and expanded-access programs, the approval is viewed as a major advance and a potential platform for RAS-driven cancers, with off-label use anticipated and ongoing development of related therapies.

via Fortune|

#fda-approval #health #oncology

health2 days ago•1 min saved

New KRAS-Targeting Drug Extends Pancreatic Cancer Survival, FDA Approves Breakthrough Therapy

The FDA has approved daraxonrasib (Rasonque) from Revolution Medicines to treat pancreatic cancer, after a phase 3 trial where patients on the daily pill had a median survival of 13.2 months versus 6.6 months on chemotherapy. The drug targets the mutated KRAS gene, present in more than 90% of pancreatic tumors, potentially altering a historically hard-to-treat cancer. About 67,000 Americans are diagnosed each year, with more than half dying within three months of diagnosis. The FDA granted Breakthrough Therapy designation in 2025.

via BBC|

#breakthrough-therapy #fda-approval #health

health2 days ago•20 min saved

FDA approves groundbreaking pancreatic cancer pill that doubles survival

The FDA has approved Revolution Medicines’ daraxonrasib (Rasonque), a daily pill that nearly doubles median survival in pancreatic cancer in a trial of about 500 patients versus chemotherapy, signaling a major advance in treating one of the deadliest cancers.

via The Washington Post|

#cancer #chemotherapy #clinical-trials

health2 days ago•24 min saved

New oral therapy from Revolution Medicines earns FDA clearance for pancreatic cancer

The FDA has approved Revolution Medicines' daily oral pill therapy to treat pancreatic cancer, marking a milestone in targeted, non-invasive cancer treatment based on recent clinical-trial results.

via AP News|

#fda-approval #health #oncology

health4 days ago•5 min saved

NAD+-Boosting Supplements May Help Pancreatic Cancer Survive Chemotherapy

A Case Western Reserve University study suggests over-the-counter NAD+-boosting derivatives NMN, NR, and NAM may enable pancreatic cancer cells to withstand chemotherapy (oxaliplatin, 5-fluorouracil, gemcitabine) in lab and animal tests. While NAD+ boosts can benefit healthy cells, cancer cells may gain energy to repair chemo damage, prompting caution for patients undergoing treatment and routine screening of supplement use by oncology teams; findings are not yet proven in humans and more research is needed.

via Fox News|

#chemotherapy #health #nad

health5 days ago•23 min saved

Charleston Gains Access to Breakthrough KRAS Pancreatic Cancer Drug

Charleston-area patients with metastatic pancreatic cancer are receiving daraxonrasib, a KRAS-targeted drug that showed in Phase 3 trials to roughly double median survival (about 13.2 months versus 6.6 with chemotherapy) via an expanded-access program before FDA approval. Terri Truere became the first local patient treated at Roper St. Francis Cancer Center, a development clinicians say could improve targeting of the KRAS mutation and potentially expand surgical options, though the drug carries notable side effects such as mouth sores, sore throat and rash. The rollout offers optimism for pancreatic cancer treatment and for next-generation KRAS therapies.

via Post and Courier|

#charleston #daraxonrasib #expanded-access

health5 days ago•59 min saved

KRAS-targeting pancreatic cancer drug boosts survival, reaches Charleston patients

A Phase 3 trial showed daraxonrasib, a KRAS-targeting therapy for metastatic pancreatic cancer, nearly doubles median survival (about 13.2 months vs 6.6) and is moving into expanded-access programs, with Terri Truere in Charleston among the first patients in the area to receive it ahead of FDA approval. The drug is not yet approved, but more SC sites are preparing to offer it; it carries notable side effects such as mouth sores and rash, and access remains limited. Doctors see promise that KRAS targeting could improve outcomes and potentially expand surgical eligibility in some patients.

via Yahoo|

#charleston #daraxonrasib #expanded-access

local-news7 days ago•4 min saved

Crawdaddy Provisions Closes After 15-Year Run as Owners Prioritize Health

Crawdaddy Provisions will not reopen its market as owners Dereck and Joan Brady shift to health-focused recovery after 15 years operating the business across a food truck, a restaurant, and a market. Dereck has been diagnosed with Stage 1 pancreatic cancer and will begin chemotherapy ahead of a Whipple procedure, while Joan is recovering from hip replacement surgery. The couple said health must come first, and thanked customers and the community as they begin this new chapter.

via Coosa Valley News|

#closure #crawdaddy-provisions #health-challenges

science7 days ago•40 min saved

KRAS-Targeted Drug Sparks Immune Defense to Prevent Pancreatic Cancer in High-Risk People

Johns Hopkins researchers report that an experimental KRAS-targeting drug was safe in a phase 1 trial of 20 people at high risk for pancreatic cancer and successfully activated KRAS-specific T-cells in 90% of participants, with immune responses persisting for about two years; while no cancers or high-risk lesions progressed during follow-up, the small study was not designed to prove prevention.

via Good News Network|

#clinical-trial #immunotherapy #kras

health-and-medicine9 days ago•7 min saved

Probiotic Bacteria Forge Localized Immunotherapy for Pancreatic Cancer

Engineered Bifidobacterium longum delivers SumIL-2 directly into pancreatic tumors to activate cancer-fighting T cells, slowing tumor growth in animal studies; the effect improves when combined with chemotherapy, radiation, or anti-PD-L1 immunotherapy, and hinges on the tumors’ low-oxygen microenvironment to localize treatment. Human safety and delivery method remain to be tested.

via Science Daily|

#bacteria-delivery #health-and-medicine #immunotherapy

science9 days ago•15 min saved

Pennsylvania teen invents blood test to detect pancreatic cancer using magnetic nanoparticles

17-year-old Audrey Zheng from North Allegheny High School developed a blood-based test that uses antibody-coated magnetic nanospheres to capture tumor-derived extracellular vesicles and test their KRAS mutations; in clinical testing it identified 87% of pancreatic cancer cases and correctly ruled out 87.5% of non-cases, earning a 2026 Regeneron Science Talent Search finalist spot and underscoring potential for earlier detection.

via The Times of India|

#early-detection #extracellular-vesicles #magnetic-nanoparticles

health11 days ago•0 min saved

Investigational pancreatic cancer pill may double survival, early data suggest

An investigational drug called daraxonrasib given to a pancreatic cancer patient at Massachusetts General Hospital is described as a potential breakthrough, with early results indicating that survival could be doubled. The report frames this as a historic advance after decades of research, though access to full details currently requires login or subscription to the Globe.

via The Boston Globe|

#cancer-treatment #clinical-trial #daraxonrasib